Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-α-2b treatment

Bendt Nielsen*, Peter Hokland, Jørgen Ellegaard, Hans Hasselbalch, Marianne Hokland

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    Natural killer cell (NK) activity in peripheral blood (PB) was followed longitudinally for up to 2 yr after initiation of low-dose IFN-α-2b therapy in nine hairy cell leukemia (HCL) patients. A whole blood NK (WB-NK) assay was employed in order to measure the NK activity per unit blood. The pretreatment WB-NK activity was consistently low, indicating that the patients' total NK activity in PB is decreased. Striking differences in WB-NK activity were observed between splenectomized and non-splenectomized patients, whereas no consistent patterns were found when using the conventional NK assay. Thus the WB-NK activity of splenectomized patients showed an immediate increase after initiation of treatment, while the activity in non-splenectomized patients decreased and remained low during the first 3-6 months. Subsequently, after reduction in spleen size, the WB-NK activity began to increase. In splenectomized patients, a second rise in WB-NK was observed after 3-6 months of therapy, coinciding with the normalisation of the peripheral blood counts. In both groups of patients incubation with IFN in vitro induced a rise in NK activity before start of treatment, which was abrogated promptly after initiation of therapy, indicating a maximal in vivo boosting of the NK cells. These differences observed indicate that the response of splenectomized and nonsplenectomized HCL patients to IFN treatment should be evaluated separately.

    OriginalsprogEngelsk
    Sider (fra-til)451-456
    Antal sider6
    TidsskriftLeukemia Research
    Vol/bind13
    Udgave nummer6
    DOI
    StatusUdgivet - 1989

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-α-2b treatment' indeholder.

    Citationsformater